Amneal gains FDA greenlight to develop Ciprodex generic for ear infections

26 Mar 2024
www.pharmaceutical-technology.com
Drug ApprovalFast TrackQualified Infectious Disease Product
Amneal gains FDA greenlight to develop Ciprodex generic for ear infections
Preview
Source: Pharmaceutical Technology
Amneal aims to develop an affordable, complex, high-value product for bacterial ear infections. Credits: goodlux/Shutterstock.com.
Amneal Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for its ciprofloxacin and dexamethasone otic suspension, a generic drug of Novartis’ Ciprodex (ciprofloxacin/dexamethasone), for the treatment of ear infections.
With the FDA approval, the New Jersey-based pharma company will develop an affordable, complex, and high-value product that reflects the “diversification of [the] business” and its evolving portfolio, said Amneal’s generics executive vice-president Andy Boyer in the 25 March press release.
An approved ANDA allows a sponsor to manufacture and market a safe and effective generic product at a lower cost than the brand-name product it references.
Ciprodex is designed to prevent bacterial DNA replication and the growth of new bacteria via the antibiotic ciprofloxacin. It suppresses inflammation by inhibiting the synthesis of cytokines associated with inflammation. As per its label, the drug is indicated to treat infections caused by susceptible isolates of the designated microorganisms in acute otitis media (AOM) and acute otitis externa (AOE) in patients aged six months and older.
Novartis reported a 62% rise in net income in 2023, increasing from $6.04bn to $8.6bn on constant currencies.
See Also:
J&J’s nipocalimab gains FDA fast track status for FNAIT risk reduction
Amneal gains FDA greenlight to develop Ciprodex generic for ear infections
Preview
Source: Pharmaceutical Technology
Takeda’s ADZYNMA gains Japanese approval for cTTP treatment
Amneal gains FDA greenlight to develop Ciprodex generic for ear infections
Preview
Source: Pharmaceutical Technology
Amneal is among several companies marketing generics of Novartis’ combination ear drop medication. India-based Dr Reddy’s launched its Ciprodex generic after receiving FDA approval in August 2020.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.